These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34545858)

  • 21. [Morphological diagnosis of endometrial intraepithelial neoplasia and expression of PTEN].
    Zhou WX; Liang ZY; Gao J; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2009 Jun; 38(6):393-6. PubMed ID: 19781346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.
    Allison KH; Upson K; Reed SD; Jordan CD; Newton KM; Doherty J; Swisher EM; Garcia RL
    Int J Gynecol Pathol; 2012 Mar; 31(2):151-159. PubMed ID: 22317873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic Importance of PAX2, ARID1A, and FOXA1 Biomarkers in Atypical Endometrial Hyperplasia.
    Yildiz ON; Topal CS; Zemheri IE
    J Coll Physicians Surg Pak; 2023 Aug; 33(8):847-851. PubMed ID: 37553920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium.
    Cirpan T; Terek MC; Mgoyi L; Zekioglu O; Iscan O; Ozsaran A
    Eur J Gynaecol Oncol; 2006; 27(4):389-92. PubMed ID: 17009632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
    Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
    Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer?
    Travaglino A; Raffone A; Saccone G; Mascolo M; Pignatiello S; Mollo A; De Placido G; Insabato L; Zullo F
    APMIS; 2019 Apr; 127(4):161-169. PubMed ID: 30803040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors.
    Ayhan A; Mao TL; Suryo Rahmanto Y; Zeppernick F; Ogawa H; Wu RC; Wang TL; Shih IeM
    J Pathol Clin Res; 2015 Jul; 1(3):186-93. PubMed ID: 27499903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endometrial intraepithelial neoplasia.
    Owings RA; Quick CM
    Arch Pathol Lab Med; 2014 Apr; 138(4):484-91. PubMed ID: 24678678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endometrial Intraepithelial Neoplasia (EIN) in endometrial biopsy specimens categorized by the 1994 World Health Organization classification for endometrial hyperplasia.
    Li XC; Song WJ
    Asian Pac J Cancer Prev; 2013; 14(10):5935-9. PubMed ID: 24289604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Viggiani M; Giampaolino P; Insabato L; Mollo A; De Placido G; Zullo F
    Arch Gynecol Obstet; 2019 Jun; 299(6):1511-1524. PubMed ID: 30915635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTEN-loss and nuclear atypia of EIN in endometrial biopsies can predict the existence of a concurrent endometrial carcinoma.
    Pavlakis K; Messini I; Vrekoussis T; Panoskaltsis T; Chrissanthakis D; Yiannou P; Stathopoulos EN
    Gynecol Oncol; 2010 Dec; 119(3):516-9. PubMed ID: 20833413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: A specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis.
    Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
    Acta Obstet Gynecol Scand; 2018 Dec; 97(12):1415-1426. PubMed ID: 30168854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
    Ørbo A; Arnes M; Lyså LM; Straume B
    Anticancer Res; 2015 Dec; 35(12):6401-9. PubMed ID: 26637849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
    Nout RA; Bosse T; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; van Eijk R; Ter Haar NT; Smit VT
    Gynecol Oncol; 2012 Sep; 126(3):466-73. PubMed ID: 22609107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Papillary mucinous metaplasia of the endometrium as a possible precursor of endometrial mucinous adenocarcinoma.
    Yoo SH; Park BH; Choi J; Yoo J; Lee SW; Kim YM; Kim KR
    Mod Pathol; 2012 Nov; 25(11):1496-507. PubMed ID: 22766790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia.
    Quick CM; Laury AR; Monte NM; Mutter GL
    Am J Clin Pathol; 2012 Nov; 138(5):678-84. PubMed ID: 23086768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathology of Endometrial Carcinoma.
    Lax SF
    Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. YTHDF2 is a novel diagnostic marker of endometrial adenocarcinoma and endometrial atypical hyperplasia/ intraepithelial neoplasia.
    Bian PP; Liu SY; Luo QP; Xiong ZT
    Pathol Res Pract; 2022 Jun; 234():153919. PubMed ID: 35512522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer.
    Raffone A; Travaglino A; Saccone G; Cieri M; Mascolo M; Mollo A; Insabato L; Zullo F
    APMIS; 2019 Sep; 127(9):597-606. PubMed ID: 31237034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
    Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
    Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.